Infinity Pharmaceuticals | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Perkins Adelene Q
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | 10-Q: Q2 2023 Earnings Report
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | DEFA14A: Others
Infinity Pharmaceuticals | DEFA14A: Others
Infinity Pharmaceuticals | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | DEFA14A: Others
Infinity Pharmaceuticals | 8-K: Current report
Infinity Pharmaceuticals | DEFA14A: Others
Infinity Pharmaceuticals | DEFA14A: Others
Infinity Pharmaceuticals | DEFA14A: Others
Infinity Pharmaceuticals | DEFA14A: Others
No Data
No Data